Product nameAnti-CD45 antibody [MEM-28] (APC/Cy7®)
See all CD45 primary antibodies
DescriptionMouse monoclonal [MEM-28] to CD45 (APC/Cy7®)
ConjugationAPC/Cy7®. Ex: 650nm, Em: 774nm
Specificityab197130 reacts with all alternative forms of Human CD45 antigen.
Tested applicationsSuitable for: Flow Cytmore details
Species reactivityReacts with: Human
Does not react with: Horse
Tissue, cells or virus corresponding to Human CD45. (Human thymocytes and T lymphocytes).
Storage instructionsShipped at 4°C. Store at +4°C. Store In the Dark.
Storage bufferPreservative: 0.097% Sodium azide
Constituents: 99% PBS, 0.2% BSA
High-grade protease free BSA
Concentration information loading...
- Anti-CD45 antibody [MEM-28], prediluted (FITC) (ab134199)
- Anti-CD45 antibody [MEM-28], prediluted (PE) (ab134202)
- Anti-CD45 antibody [MEM-28] (PerCP/Cy5.5®) (ab157309)
- Anti-CD45 antibody [MEM-28] (PE/DyLight™ 594) (ab223183)
- Anti-CD45 antibody [MEM-28] (Alexa Fluor® 647) (ab239276)
- Anti-CD45 antibody [MEM-28] (PE/Cy7®) (ab239317)
- Anti-CD45 antibody [MEM-28] (APC) (ab28106)
- Anti-CD45 antibody [MEM-28] (Biotin) (ab28107)
- Anti-CD45 antibody [MEM-28] (PerCP) (ab65952)
- Anti-CD45 antibody [MEM-28] (ab8216)
Our Abpromise guarantee covers the use of ab197130 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Flow Cyt||Use 4µl for 106 cells.
(or in 100 μl whole blood).
FunctionProtein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN.
Involvement in diseaseDefects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain.
Sequence similaritiesBelongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
Contains 2 fibronectin type-III domains.
Contains 2 tyrosine-protein phosphatase domains.
DomainThe first PTPase domain interacts with SKAP1.
modificationsHeavily N- and O-glycosylated.
Cellular localizationMembrane. Membrane raft. Colocalized with DPP4 in membrane rafts.
- Information by UniProt
- B220 antibody
- CD 45 antibody
- CD45 antibody
ab197130 has not yet been referenced specifically in any publications.